Navigation Links
Data: ATSP-7041 as first-in-class p53 pathway re-activator for solid/ hematologic cancers
Date:8/15/2013

CAMBRIDGE, Mass., August 15, 2013 Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein. P53, known as "the guardian of the genome" because it repairs damaged DNA or triggers cell death in pre-cancerous cells, is one of the most important known tumor suppressors, as it is shown to be inactivated in virtually all human cancers. As 50% of all cancers circumvent P53's protective mechanisms by the over-expression of the inhibitory proteins MDM2 and MDMX, Aileron's stapled peptide is novel in that it can selectively bind to and inhibit both proteins equally and, thereby, restore the P53 function. The research, published in Proceedings of the National Academy of Sciences (PNAS), provides the first detailed publication by Aileron of one of its cell penetrating peptides that is a precursor molecule to one that the company is developing for the treatment of both liquid and solid tumors. The paper, entitled "Stapled α−Helical Peptide Drug Development: A Potent Dual Inhibitor of MDM2 and MDMX for p53-Dependent Cancer Therapy," expands on data reported by the company in poster presentations at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics and the 2013 International MDM2 workshop in Cambridge, England.

"As evidenced by the multitude of research and clinical efforts, the full activation of p53 has been the goal of cancer researchers for decades given its [ubiquitous] role in all human cancers" said Joseph A. Yanchik III, president and chief executive officer of Aileron Therapeutics. "Our stapled peptide drug will be the first full-activator of wild type p53 of its kind to our knowledge to enter clinical trials. Our unique approach to restore p53 activity through direct inhibition of both MDM2 and MDMX has the potential to deliver greater efficacy and safety than existing small molecule approaches, which are primarily limited to inhibition of just MDM2. We look forward to advancing the p53 program into clinical trials next year that will represent our second stapled peptide drug to enter human clinical trials."

Key findings from the paper showed that ATSP 7041:

  • suppressed tumor growth in animal models of multiple human xenograft models, including breast cancer and bone cancer

  • is an equipotent dual inhibitor of MDM2 and MDMX that restores p53 specific activity

  • is a peptide that efficiently penetrated cell membranes and exhibited a more durable on mechanism effect on p53 signaling than small-molecule MDM2-selective inhibitors

  • exhibited favorable drug-like and pharmacokinetic properties that can support convenient clinical dosing regimens [including the potential for once-weekly dosing]


'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Related medicine news :

1. New concussion data: 2 biomarkers better than 1
2. Cellular pathway linked to diabetes, heart disease
3. Unusual protein helps regulate key cell communication pathway
4. Mutant Kras drives pancreatic cancer maintenance via metabolic pathways
5. Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved
6. VCU researchers identify changes in cholesterol metabolic pathways
7. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
8. Inhibiting Hedgehog signaling pathway may improve pancreatic cancer treatment
9. Global Energy Assessment identifies pathways to a sustainable energy future
10. Grb2 holds powerful molecular signaling pathway in check
11. Researchers block pathway to cancer cell replication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... A book about the self-discovery of one’s limitless creative power, “ Unleash Your ... give readers the courage they need to embrace their creativity and unleash it as ... my life to learn and create what I set my heart with no limits ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... "ProDrop 3D ... projects to the next level," said Christina Austin - CEO of Pixel Film Studios. ... Studios. With ProDrop 3D Abstract have the ability to generate and manipulate three-dimensional shapes ...
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical therapists ... physical therapy professional and every clinic has a duty to perform at the highest ... competitive industry is also essential. The solution that many physical therapy leaders turn to ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... “ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... that considers individuals’ genetic characteristics and the physical and behavioral worlds in ... in sync. In personalized medicine, diagnosing an individual’s disease depends on accurately ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... market growth is the emergence of new treatments. Cardax, ... therapies for osteoarthritis treatment. The therapy is expected to ... Arthritis Research UK is conducting studies to develop new ... study, where the genes involved in osteoarthritis are being ...
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology: